Related Experiment Video
Updated: May 10, 2026
Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
Published on: March 22, 2017
Recombinant human decorin upregulates p57KIP² expression in HepG2 hepatoma cell lines
Abdu Selim Hamid1, Jinran Li, Yali Wang
1Central Laboratory, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China.
Abstract:
Increasing the expression of cyclin-cyclin-dependent kinase inhibitors (cyclin-CDK) using small molecule inhibitors is a therapeutic strategy used to suppress cancer cell growth. Decorin (DCN), a functional component of the extracellular matrix, has been implicated in the suppression of cell proliferation by upregulating p21, a cyclin-CDK inhibitor. The purpose of this study was to examine the effect of recombinant decorin on the reactivation of p57KIP2, whose expression is silenced in hepatocellular carcinoma (HCC). Cell viability assay, cell cycle analysis, apoptosis assay and quantitative real time-PCR experiments were performed in three groups of HepG2 human cells: Uninfected HepG2 cells (control group), pcDNA3.1 vector-infected HepG2 cells (pcDNA3.1 group) and pcDNA3.1-DCN-infected HepG2 cells (pcDNA3.1‑DCN group). Our results revealed that recombinant human decorin inhibited cell proliferation, induced G0/G1 phase arrest and induced apoptosis by increasing the expression of caspase-3 in the pcDNA3.1-DCN group. The expression of p57KIP2 mRNA in the pcDNA3.1-DCN group was higher than in the pcDNA3.1 and control groups (P<0.05); however, there was no statistically significant difference between the control and pcDNA3.1 groups (P>0.05). In conclusion, recombinant human decorin reactivated p57KIP2 expression in HepG2 cells. As the expression level of p57KIP2 is downregulated in HCC, our finding may serve as a basis for the therapy and prognosis of HCC, although further studies are required.
Insights
Recombinant decorin (DCN) reactivated the tumor suppressor p57KIP2 in hepatocellular carcinoma (HCC) cells. This finding suggests DCN as a potential therapeutic agent for HCC by restoring cell cycle control.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cyclin-dependent kinase inhibitors (CKIs) are crucial for cell cycle regulation.
- Small molecule inhibitors targeting cyclin-CKIs are a therapeutic strategy for cancer.
- Decorin (DCN), an extracellular matrix protein, upregulates p21, a CKI, inhibiting cell proliferation.
Purpose of the Study:
- To investigate the effect of recombinant decorin (DCN) on p57KIP2 expression in hepatocellular carcinoma (HCC).
- To determine if DCN can reactivate silenced p57KIP2 in HCC cells.
Main Methods:
- Cell viability, cell cycle, and apoptosis assays were performed on HepG2 cells.
- Quantitative real-time PCR (qRT-PCR) was used to measure mRNA expression levels.
- Three groups were studied: control, pcDNA3.1 vector-infected, and pcDNA3.1-DCN-infected HepG2 cells.
Main Results:
- Recombinant DCN inhibited HepG2 cell proliferation and induced G0/G1 phase arrest.
- DCN treatment led to increased apoptosis via caspase-3 upregulation.
- p57KIP2 mRNA expression was significantly higher in the DCN-treated group compared to controls.
Conclusions:
- Recombinant human decorin effectively reactivated p57KIP2 expression in HepG2 cells.
- The findings indicate that DCN may serve as a therapeutic basis for HCC, given p57KIP2's downregulated expression in this cancer.
- Further research is warranted to validate DCN's therapeutic potential in HCC.
